[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 22.25 22.00 22.50 22.25 22.25 22.25 144,490 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.8 -1.2 - 176

Scancell Share Discussion Threads

Showing 48051 to 48074 of 48075 messages
Chat Pages: 1923  1922  1921  1920  1919  1918  1917  1916  1915  1914  1913  1912  Older
DateSubjectAuthorDiscuss
27/9/2021
10:50
The 'GREEN LIGHT' turning RED ... a WARNING - "Take Brexit, a major decision BASED on LIES... One could say that 'the so called leaders' took this as 'a GREEN LIGHT' that LIES were their 'Way ahead' = Just LIE. Governments / institutions / War lords have ALWAYS LIED.. but, at least they TRIED to hide the FACT that they were telling LIES." Was this the GREEN LIGHT to end FREEDOM ??? What happened to 'democratic Government'... Government by CONSENT ??? Now = NEW EMERGENCY MEASURES... NO parliamentary consent... Just ENFORCED, no debate - NEW EMERGENCY MEASURES... YOU WILL OBEY First - Covid RULES.. NEW EMERGENCY MEASURES.....YOU WILL OBEY Now - Fuel crisis = NEW EMERGENCY MEASURES....YOU WILL OBEY What next - Climat E change - NEW EMERGENCY MEASURES... YOU WILL OBEY ??? Vac seems - NEW EMERGENCY MEASURES... YOU WILL OBEY .... At least it appeared with Brexit, 'The PEOPLE had a choice' Now = Government by NEW EMERGENCY MEASURES.. YOU have NO choice
the real lozan
27/9/2021
10:05
Marcus - funnily enough I was looking at Scancells ex CEO's LinkdIn page over the weekend & recent activity shows he "liked" the Clarity IPO..... Https://uk.linkedin.com/in/cliffholloway Https://www.afr.com/companies/healthcare-and-fitness/clarity-pharmaceuticals-to-hit-asx-in-august-20210720-p58b98 As we know Holloway left Oz to take the CEO position with Scancell. The relatively suddenness of his departure & the Zakari set up all remains a mystery ;) It's a small world out there.
gooosed
27/9/2021
10:02
Artemida is a slight corruption of Artemis (aka Diana the chaste goddess of the hunt) Turned Callisto, one of her 'chaste' nymphs, into a BEAR after Jupiter had got her up the duff. Splashed water on Actaeon, who metamorphosed into a stag and was torn to shreds by his own dogs. He had unwittingly copped an eyeful when she was at her toilet. Saw an excellent exhibition in that cultural tundra 'Landan'. Check out the action on this exhibition trailer featuring the distinctly easy-on-the-eye Anna Friel. Oh yes! htTps://www.youtube.com/watch?v=QAzQ5IFSbeE
goyathlay
27/9/2021
09:50
Dr Robert Miller is a Managing Partner in Artemida Pharma, a drug development consultancy and has represented a number of companies providing strategic expertise, medical management and clinical development support for both small and large pharmaceutical and biotechnology companies during his 30- year career in the industry, particularly in the fields of oncology and immune-oncology HTTPS://www.artemidapharma.com/services/clinical 17 Nov 2020 — Appointment of Dr Gillies O'Bryan-Tear as Chief Medical Officer and Dr Robert Miller as Medical. Director at Scancell
marcusl2
27/9/2021
09:40
The UK biotech sector is a bright beacon of hope for our future economic wealth, it matches the IT sector. But they [companies] get bought early, often at around the $1 billion mark, because they don’t have the scale to compete and grow themselves. That’s a shame because the ownership often passes to a foreign nation. In the U.S. it’s a much bigger market and investors have much deeper pockets, maybe three to five times the size. They have a much better informed array of analysts and former scientists who are venture capitalists. We have a handful of very well-qualified, scientific VCs. The strategic decision when you have a biotech company in Europe is always: do you list on Nasdaq to get a valuation three to five times higher – but you have to deal with all the regulatory red tape that that entails and costs – or do you stick with a European listing? That’s a common decision point all biotech companies in Europe have to reach and take. HTTPS://www.nurole.com/news_and_guides/gillies-obryan-tear-chair-university-college-london Gillies O'Bryan-Tear occupies the position of Chief Medical Officer of Scancell Holdings Plc. He is also on the board of Clarity Pharmaceuticals Ltd. He previously occupied the position of Vice President-Research & Development of GlaxoSmithKline Biologicals SA, Chief Medical Officer of Algeta ASA, Medical Director for Bristol-Myers Squibb Pharmaceuticals Ltd. and Interim Medical Director at Genzyme Therapeutics Ltd.
marcusl2
27/9/2021
09:23
hTTps://youtu.be/p5Wx2pgno5o
inanaco
27/9/2021
09:19
No answer Gazza its not a trick question is it ............. ? inanaco27 Sep '21 - 09:04 - 45130 of 45133 Edit 0 0 0 Bermuda posts on his shares, Ivy does ... you don't why is scancell so special ? I cannot apply this statement of yours Gazza to scancell .................... """"I agree with your observations re focus on commercialisation rather than the pursuit of extending and perfecting the science."""" please explain what part of the pre-clinical work you would Miss out ?
inanaco
27/9/2021
09:13
Lol ... we are PI ... even with my holding ... still a Pi ...
inanaco
27/9/2021
09:12
...not yet
emptyend
27/9/2021
09:05
EE .. i think you are getting a little bit a head of yourself or Have you a seat on the board of Red Mile
inanaco
27/9/2021
09:04
Bermuda posts on his shares, Ivy does ... you don't why is scancell so special ? I cannot apply this statement of yours Gazza to scancell .................... """"I agree with your observations re focus on commercialisation rather than the pursuit of extending and perfecting the science."""" please explain what part of the pre-clinical work you would Miss out ?
inanaco
27/9/2021
09:03
Of course, if the question of leadership proves to be an issue, that would be "easy" to resolve by merging Scancell with another company. I think we can count on Redmile doing that if they determine they need to......
emptyend
27/9/2021
08:59
"Why do you never mention your other Shares ?"Any reason why I should?
gazza
27/9/2021
08:59
Inan, I repeat, I am not invested in VAL and haven't been for years. My post was in the context of Scancell. If you want to argue the pros and cons of VAL I suggest you do it on the VAL board. I think it's rather poor if you can only make a case for something on the basis that everything else is worse.
gazza
27/9/2021
08:58
Gazza Why do you never mention your other Shares ? or post on them ?
inanaco
27/9/2021
08:53
its your post !!! Gazza """"I agree with your observations re focus on commercialisation rather than the pursuit of extending and perfecting the science."""" so an example of an incomplete science package which dim wit shareholders think is worth a billion .... is VAL I cannot apply this statement to scancell .................... """"I agree with your observations re focus on commercialisation rather than the pursuit of extending and perfecting the science.""""
inanaco
27/9/2021
08:50
Inan, I got out of Val years ago as you well know. Are you unable to stick to the topic - Scancell, the pros and cons, the risk vs potential rewards, progress in the clinic. Plenty of sub topics. Also, focus on the present and future rather than history. The past has gone and you can't change it, only learn from it (well some of us!)
gazza
27/9/2021
08:44
and How is that going for VAL ...gazza """"I agree with your observations re focus on commercialisation rather than the pursuit of extending and perfecting the science.""""
inanaco
27/9/2021
08:42
"the entire point of why we are Risk free"No share is risk free. You really are a clown if you believe it is.
gazza
27/9/2021
08:42
Yes EE over my long career I have seen scientists who are absolutely brilliant at doing what they do best “ doing science” but they normally do not make very good pharma leaders.There are always exceptions of course and the jury is still out in LD in this respect. I am sure she will be very keen to progress the trial work but if she had exited her Nottingham Uni position and concentrated 100% on SCLP then that would be a strong indicator of her determination to do this. It is also about being an inspirational leader which yes she may well be amongst the staff and some SH but it is how she performs in financial circles which is equally important. It does take all types a CEO of a FTSE Compsny I know in this space is as boring as anything but he delivers. He started working in the warehouse and never had a chemistry set but he has led a major pharma for many years now
ivyspivey
27/9/2021
08:40
Ivy, Empty, I agree with your observations re focus on commercialisation rather than the pursuit of extending and perfecting the science. It was the apparent lack of progress in the commercial area that caused me to have concerns about appointing the Chief Scientific Officer as CEO. So far these concerns seem to have been unfounded, let's hope it continues. It's good to be able to discuss the pros and cons like grown ups!
gazza
27/9/2021
08:36
EE but if the IP had any value it would still be picked up as an asset in any sale .. look at Provenge the entire point of why we are Risk free at this level is because of the data already collected on the immunobody platform .. I appreciate that to get that data the Patent Time has been eaten into .. but we still had exclusivity in the US under orphan status but now the FC to Fc .... has given us a brand new patent ... "significant" has enormous value if its significant .... and Lindy does not "ramp"
inanaco
27/9/2021
08:30
Exactly. I've seen this before in a company controlled by the scientist who developed the IP. Both the IP (a promising and cheap cancer treatment) and the company's investors were wasted, because the founder refused to be diluted. (Coincidentally this was a company called Ivy ;-))I hope that LD has her eyes firmly fixed on getting product to market. I'm hopeful (based on some limited interactions in recent months) but I want to see RNS proof....
emptyend
27/9/2021
08:19
Complete Drivel ... Ivy because unless you get the vaccine to elicit the correct T cell it just will not flip the environment and won't work .. looking at a potential trial failure because you failed to understand that environment .. rushed ... potentially destroying the market before you have even started as money does not respect failure . Your own failing in being able to value Orph has shown you are not "experienced in this market" I know you like to big yourself up but your posts are really highlighting just how naive you are as an investor especially as i had explained why Orph would not achieve your goals !! would you like a reprint ? you lost your shirt in MTFB because you backed a trial against a off patent drug, leaving no room for error "extreme risk" that you could even create a market for the product let alone get it approved, especially as it was only 90% effective against the off patent. It does not matter if that was in the trial tolerance it still did not out perform an off patent antibiotic You conned folks on here that you are a 500,000 share holder in SCLP ... yet when i questioned you on it, you didn't even recognise the number, yet it was one of your claims. It then transpired you started buying at 27p a few £ 1000's, why on earth folks listen to your bull is beyond me.
inanaco
Chat Pages: 1923  1922  1921  1920  1919  1918  1917  1916  1915  1914  1913  1912  Older
ADVFN Advertorial
Your Recent History
LSE
SCLP
Scancell
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210927 10:01:10